Product Description
For Major Depressive Disorder
Mechanisms of Action: 5-HT Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sunshine Lake Pharma
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20211474 |
CTR20211474 | N/A |
Recruiting |
Depressive Disorder |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT04623814 |
HEC113995-P-04/CRC-C2006 | P1 |
Completed |
Depressive Disorder, Major |
2020-08-12 |
88% |
2020-11-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04591301 |
HEC113995PA•H2O-P-01/CRC-C1910 | P1 |
Completed |
Depressive Disorder, Major |
2019-12-06 |
2020-10-21 |
Primary Endpoints|Treatments |
|
NCT04984512 |
HEC113995-P-5 | P3 |
Unknown status |
Depressive Disorder, Major |
2024-04-01 |
19% |
2024-05-02 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|